The ‘Rapid Intervention with Glyceryl Trinitrate in Hypertensive Stroke Trial-2’ (RIGHT-2)

• Professor Philip MW Bath, University of Nottingham
• Professor Timothy England, University of Nottingham
• Professor John Potter, University of East Anglia
• Professor Christine Roffe, North Staffordshire Combined Healthcare Trust
• Professor Alan Montgomery, University of Nottingham
• Professor Thompson G Robinson, University of Leicester
• Dr Chris I Price, University of Newcastle upon Tyne
• Professor Joanne M Wardlaw, University of Edinburgh
• Professor A Niroshan Siriwardena, University of Lincoln

• To compare the difference between GTN and no GTN in death, disability, dependency, mood, cognition, and quality of life.

Secondary objectives

• To assess the safety and tolerability of GTN in suspected ultra-acute stroke.
• To compare the difference in peripheral blood pressure, central blood pressure, heart rate, and its derivatives between patients randomised to GTN or no GTN.

Bath PM, Scutt P, Anderson CS, Ankolekar A, Appleton JP, Berge E, Cala L, Dixon M, England TJ, Godolphin PJ, Havard D, Haywood L, Hepburn T, Krishnan K, Mair G, Montgomery AA, Muir K, Phillips SJ, Pocock S, Potter J, Price CI, Randall M, Robinson TG, Roffe C, Rothwell PM, Sandset EC, Sanossian N, Saver JL, Shone A, Siriwardena AN, Wardlaw JM, Woodhouse LJ, Venables G, Sprigg N et al (2019). Prehospital transdermal glyceryl trinitrate in patients with ultra-acute presumed stroke (RIGHT-2): an ambulance-based, randomised, sham-controlled, blinded, phase 3 trial. The Lancet (online first) http://dx.doi.org/10.1016/S0140-6736(19)30194-1.

Bath PM, Woodhouse LJ, Krishnan K, Appleton JP, Anderson CS, Berge E, Cala L, Dixon M, England TJ, Godolphin PJ, Hepburn T, Mair G, Montgomery AA, Phillips SJ, Potter J, Price CI, Randall M, Robinson TG, Roffe C, Rothwell PM, Sandset EC, Sanossian N, Saver JL, Siriwardena AN, Venables G, Wardlaw JM, Sprigg N (2019). Pre-hospital transdermal glyceryl trinitrate for ultra-acute intracerebral haemorrhage- data from the RIGHT-2 trial. Stroke (online first). https://doi.org/10.1161/STROKEAHA.119.026389

Conference presentations:

Website: http://right-2.ac.uk/

Economic: potential for reduction in costs of hospital treatment and long term health and social care from stroke.

Social: potential for prevention of long-term disability and suffering from stroke.